



RECEIVED

JUN 05 2003 P444 0003

GOSO/GSL/ob

TECH CENTER 1600/2900

Paper No.: _____

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Inventor(s): HUANG, Dong; QI, Dong Feng
Title: NOVEL AGLYCON DAMMARANE SAPOGENINS, THEIR USE AS
ANTI-CANCER AGENTS, AND A PROCESS FOR PRODUCING SAME
Serial No.: 09/982018
Filed: 19 October 2001
Examiner: Qazi, Sabiha Naim Art Unit: 1616
Date: 30 May 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

AMENDMENT TRANSMITTAL LETTER

Enclosed is an Amendment for the above application. The fee has been calculated as shown below.

Claims As Amended						
	1	2	3			
	No. after amendment	No. paid for previously	Present Extra	Small Entity Rate	Fee	
Total Claims > 20	62*	- 34**	= 28	\$ 9.00	\$252	
Indep. Claims > 3	11 *	- 8***	= 3	\$42.00	\$126	
TOTAL ADDITIONAL FEE					\$378	


- (X) Please charge our Deposit Account No. 02-1037 in the amount of **US\$378**.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the filing of this application and recording any assignment filed herewith, or credit over-payment, to Account No. 02-1037.

Respectfully submitted,

By:

Gerald O.S. Oyen
Registration No. 27,280
tel: 604.669.3432 ext. 218
fax: 604.681.4081
e-mail: goyen@patentable.com

Vancouver, B.C.
CANADA



RECEIVED

JUN 05 2003

TECH CENTER 1600'2P444 0003
GOSO/GSL

#8/B
6/9/03
NW

Paper No.: _____

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Inventor(s): HUANG, Dong; QI, Dong Feng

Title: NOVEL AGLYCON DAMMARANE SAPOGENINS, THEIR USE AS
ANTI-CANCER AGENTS, AND A PROCESS FOR PRODUCING SAME

Serial No.: 09/982018

Filed: 19 October 2001

Examiner: QAZI, Sabiha Naim

Art Unit: 1616

Date: 29 May 2003

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

AMENDMENT

Responsive to the Office Action mailed 12 February 2003 as extended by the accompanying Petition (if applicable), please amend this application as follows:

Amendments to the Specification: begin on page 2 of this paper.

Amendments to the Drawings: begin on page 7 of this paper.

Amendments to the Claims: begin on page 8 of this paper.

Remarks: begin on page 19 of this paper.

06/03/2003 YPOLITE1 00000117 021037 09982018

01 FC:2202 252.00 CH
02 FC:2201 126.00 CH